This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2007 Apr;14(2):66-9.

doi: 10.3747/co.2007.108.

Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies

W G Jiang¹

Affiliations

PMID: 17576468
PMCID: PMC1891202
DOI: 10.3747/co.2007.108

Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies

W G Jiang. Curr Oncol. 2007 Apr.

. 2007 Apr;14(2):66-9.

doi: 10.3747/co.2007.108.

Author

W G Jiang¹

Affiliation

¹ Metastasis andAngiogenesis Research Group, Wales College ofMedicine, Cardiff University, Cardiff,United Kingdom. jiangw@cf.ac.uk

PMID: 17576468
PMCID: PMC1891202
DOI: 10.3747/co.2007.108

No abstract available

PubMed Disclaimer

Similar articles

Growth factor attenuation of IFNgamma-mediated hepatocyte apoptosis requires p21waf-1.
McCullough CT, Tura BJ, Harrison DJ. McCullough CT, et al. Int J Exp Pathol. 2006 Aug;87(4):275-81. doi: 10.1111/j.1365-2613.2006.00481.x. Int J Exp Pathol. 2006. PMID: 16875492 Free PMC article.
Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Miyata Y, et al. Hum Pathol. 2009 Apr;40(4):496-504. doi: 10.1016/j.humpath.2008.09.011. Epub 2009 Jan 3. Hum Pathol. 2009. PMID: 19121849
Herbacetin, a constituent of ephedrae herba, suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation.
Hyuga S, Hyuga M, Yoshimura M, Amakura Y, Goda Y, Hanawa T. Hyuga S, et al. Planta Med. 2013 Nov;79(16):1525-30. doi: 10.1055/s-0033-1350899. Epub 2013 Sep 30. Planta Med. 2013. PMID: 24081687
Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Gelsomino F, et al. Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24355409 Review.
Hepatocyte growth factor as potential cardiovascular therapy.
Nakagami H, Kaneda Y, Ogihara T, Morishita R. Nakagami H, et al. Expert Rev Cardiovasc Ther. 2005 May;3(3):513-9. doi: 10.1586/14779072.3.3.513. Expert Rev Cardiovasc Ther. 2005. PMID: 15889978 Review.

See all similar articles

Cited by

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.
Corn PG. Corn PG. Cancer Manag Res. 2012;4:183-93. doi: 10.2147/CMAR.S32839. Epub 2012 Jul 25. Cancer Manag Res. 2012. PMID: 22904640 Free PMC article.
Effects of microRNA-29a on retinopathy of prematurity by targeting AGT in a mouse model.
Chen XK, Ouyang LJ, Yin ZQ, Xia YY, Chen XR, Shi H, Xiong Y, Pi LH. Chen XK, et al. Am J Transl Res. 2017 Feb 15;9(2):791-801. eCollection 2017. Am J Transl Res. 2017. PMID: 28337307 Free PMC article.
Aptamer-based search for correlates of plasma and serum water T₂: implications for early metabolic dysregulation and metabolic syndrome.
Patel V, Dwivedi AK, Deodhar S, Mishra I, Cistola DP. Patel V, et al. Biomark Res. 2018 Sep 17;6:28. doi: 10.1186/s40364-018-0143-x. eCollection 2018. Biomark Res. 2018. PMID: 30237882 Free PMC article.

References

1. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–3. - PubMed
1. Gherardi E, Stoker M. Hepatocyte and scatter factor. Nature. 1990;346:228. - PubMed
1. Jiang WG, Parr C, Martin TA, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53:35–69. - PubMed
1. Jiang WG, Davies G, Martin TA, et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 2005;16:723–8. - PubMed
1. Kajiya K, Hirakawa S, Ma BJ, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005;24:2885–95. - PMC - PubMed

LinkOut - more resources

Full Text Sources